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Although malignant islet-cell tumors are uncommon, they 
are an importani group of pancreatic neoplasms because 
appropriate treatment can often result in effective pallia- 
tion even though cure is infrequent. In general, these 
tumors are relatively slow growing so that a combination of 
surgical and chemotherapeutic measures may prove very 
beneficial. In some patients with tumors hypersecreting 
insulin, gastrin, glucagon, or vasoactive intestinal poly- 
peptide (VIP), the hormonal effects of the neoplasm can be 
life-threatening. Surgical treatment must, therefore, con- 
sider both the functional and malignant characteristics of 
the individual tumor. In many patients with functional 
tumors, surgical debulking of the primary tumor may be 
indicated even when a curative resection cannot be accom- 
plished. Some malignancies may be cured by an appropri- 
ate pancreatic resection even when peripancreatic lymph 
nodes are already involved. Although a Whipple procedure 
is not indicated when hepatic metastases are present, this 
procedure may cure tumors localized to the pancreatic 
head and/or peripancreatic lymph nodes. Because hepatic 
metastases are usually multiple and involve both lobes, 
liver resections, other than wedge excisions of peripherally 
located functional metastases, are not indicated. Malignant 
nonfunctioning islet-cell tumors are probably best treated 
with systemic or regional chemotherapy when metastatic. 
Surgical resections or bypass procedures may be infre- 
quently useful in those cases in which the primary tumor 
causes either duodenal or bile duct obstruction: The most 
effective methods used to control hepatic metastases are 
systemic and hepatic arterial chemotherapy. An alternative 
is selective hepatic artery embolization. Recently, an 
implantable hepatic arterial infusion pump has been used 
with encouraging results in this group of patients. The 
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chemotherapeutic agents that have been most effective in 
the treatment of hepatic metastases include streptozotocin, 
DTIC, and fluorouracil. 
Since the diagnosis and surgical t reatment  of  an 
islet-cell tumor  causing hypoglycemia  in 1926 and 
the description of the Zollinger-Ellison syndrome in 
1955, there has been an ever-increasing interest in 
islet-cell tumors,  their secretions, and their biologi- 
cal behavior  [1]. Other tumor  syndromes  have been 
defined including the Verner-Morr ison or watery  
diarrhea syndrome in 1958 and the glucagonoma 
syndrome in 1966 [2, 3]. Islet-cell tumors  secreting 
pancreat ic  polypeptide,  somatostat in,  ACTH,  
calcitonin, and serotonin have also been identified 
through clinical and immunohis tochemical  studies 
of  specimens excised at operat ions or autopsies [4, 
5]. It is est imated that 10-15% of all islet-cell tumors  
are nonfunctional or at least secrete no hormone 
that is detectable by available immunoassays .  De- 
spite the variety of  different clinical syndromes 
caused by these tumors,  their biological behavior  is 
generally similar in that they are usually slow grow- 
ing. When malignant, they usually metastas ize  to 
the regional lymph nodes and to the liver. Their  
response to radiation and chemotherapy  is also 
predictably similar. All islet-cell tumors,  regardless 
of  function, may arise sporadically or occur  as a 
component  of  the M E N  I syndrome.  However ,  
there are important  differences in the incidence of 
malignancy, effects of hormone  secretion, and  re- 
sponse to therapy that are important  clinically (Ta- 
ble I). In this report ,  malignant islet-cell carcinomas 
will be considered in relationship to their functional 
syndromes and their occurrence  sporadically and in 
the M E N  I syndrome.  Therapeut ic  emphasis  will 
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stress both antihormonal and antitumor manage- 
ment. 
Insulinomas 
Insulinomas have been considered the most com- 
mon islet-cell tumor, with nearly 3,000 cases re- 
ported since 1926. Most insulinomas are benign and 
can be cured by enucleation or partial pancre- 
atectomy. In most series, only 5-10% are malignant 
as determined by local invasion and lymph node, 
liver, or systemic metastases. In a 1950 collected 
review of 398 cases, it was found that 37 (9.3%) 
were malignant [6]. Stefanini et al. [7, 8], in their 
1974 review of 1,067 cases, found that 15% were 
malignant with about one-third having metastasized 
at the time of initial diagnosis. Malignancy was 
demonstrated in 11% of insulinomas at the Mayo 
Clinic as determined by lymphatic or hepatic metas- 
tases or by perineural and/or vascular invasion [6]. 
Since 1960 we have treated 69 patients with 
proven hyperinsulinism at the University of Michi- 
gan [9]. Four of these patients (6%) were proven to 
have malignant insulinomas as determined by 
metastases to either lymph nodes or liver. Two 
additional patients, of whom one was an MEN ! 
patient, had locally invasive tumor involving pan- 
creatic tissue but were cured by resection. If these 
2 patients are included as malignant insulinomas, 
8.6% of our total insulinoma population had malig- 
nant islet-cell tumors. Islet-cell malignancies caus- 
ing hyperinsulinism and hypoglycemia were spo- 
radic in 4 patients and familial in 2, occurring in 
association with the MEN I syndrome. Three pa- 
tients with sporadic malignant insulinomas had liver 
metastases at the time of diagnosis. One of the 
MEN I patients had multicentric islet-cell carci- 
noma with regional lymph node involvement. Sur- 
prisingly, his symptoms were relatively mild. 
Hypoglycemic symptoms could not be elicited by a 
standard 72-hour fast. His maximum insulin level 
was 15 fxU/ml, a value that is much lower than that 
found in most patients with symptomatic malignant 
insulinomas. At operation, it was possible to do en 
bloc resection of his distal pancreas along with 
regional lymph nodes. A second islet-cell tumor 
was enucleated from the head of the pancreas. The 
peripancreatic lymph nodes contained metastatic 
islet-cell carcinoma, but the patient has done well 
during a 15-year period of follow-up. The other 
MEN I patient, a 40-year-old woman, underwent 
resection of the distal body and tail of the pancreas. 
Two small tumors were found and one contiguous 
lymph node was found to contain islet-cell tumor. 
She, too, has remained symptom free for a period of 
follow-up of 10 years. It is noteworthy that of all 
patients with insulinomas, only 4% have the MEN I 
syndrome [1]. This low incidence of the MEN I 
syndrome in patients with insulinoma contrasts 
with the 30--40% incidence of parathyroid and pitui- 
tary disease in patients with gastrinomas [4, 10-14]. 
In addition to the 3 patients with sporadic 
insulinomas and liver metastases, a 55-year-old 
patient was found to have a locally invasive tumor 
in the tail of his pancreas. He was treated by 
resection when it became apparent that enucleation 
was not feasible. Following that operation, he has 
done well for a 5-year period without evidence of 
recurrence. 
The symptoms of malignant insulinoma are simi- 
lar to those in patients with benign adenomas or 
diffuse islet-cell hyperplasia. They consist of 
neuroglucopenic symptoms as well as symptoms 
due to adrenergic stimulation. In patients with ma- 
lignant islet-cell tumors, the onset of symptoms 
may be more acute and rapidly progressive than in 
patients with benign disease. As noted above, 
nearly all patients with proven malignancy have 
lymph and/or liver metastases. Whether local inva- 
sion without lymph node involvement is sufficient 
evidence to classify these tumors as malignant is 
not clear. In our experience, patients with tumors 
having invaded locally into surrounding pancreatic 
parenchyma have done well after resection without 
evidence of tumor recurrence. 
The biochemical diagnosis of hyperinsulinism is 
made on the basis of fasting hyperglycemia and the 
determination of immunoreactive insulin-to-glucose 
ratios. If this ratio is greater than 0.3, the diagnosis 
can usually be made within the first 24 hours of a 
72-hour fast. Of our total insulinoma patients, 
nearly 90% could be diagnosed within the first 24 
hours [9, 15]. The only exception was a malignant 
insulinoma occurring in the MEN I patient dis- 
cussed earlier. It should be emphasized that abso- 
lute increases in insulin levels are not found in all 
patients with proven tumors, primarily because of 
the sporadic secretion of insulin by the tumor. The 
C-peptide level is a valuable adjunctive biochemical 
study in borderline patients because of its longer 
plasma half-life. It is particularly useful when the 
insulin levels are normal in a hypoglycemic patient 
who is suspected of having an insulinoma. When 
the levels of insulin are elevated in association with 
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hypoglycemia, the diagnosis can be made with 
assurance. The normal level of fasting insulin in our 
laboratory is 20 ~xU/ml. The insulin levels in 51 
patients with insulinomas proven at operation 
ranged from ll to 179 ~xU/ml when the patients 
were hypoglycemic. Three patients with sporadic 
islet-cell malignancies had insulin levels of 59, 64, 
and 1,260 IxU/ml, respectively. The extremely high 
level seen in the third patient suggests the presence 
of malignancy. However, levels in the first two 
patients with hepatic metastases were similar to 
those seen in patients with benign disease. 
Pro-insulin values may help to confirm the diag- 
nosis of malignant insulinoma [2]. Normally this 
hormone comprises 10-15% of total insulin and 
rarely constitutes more than 22% of the total im- 
munoreactive insulin (IRI) in normal patients. 
Insulin-secreting neoplasms typically release exces- 
sive amounts of pro-insulin into the circulation. 
Therefore, estimation of the percentage of pro- 
insulin to insulin may be helpful in predicting the 
possibility of malignancy, especially when it ex- 
ceeds 40%. Since 1960, the pro-insulin component 
exceeded 22% of the total fasting IRI in more than 
80% of patients with proven tumors [9]. In patients 
with islet-cell carcinomas, an even higher propor- 
tion is usually found in the plasma. However, in any 
individual patient, the percentage of pro-insulin 
compared to the total IRI may not accurately dif- 
ferentiate malignant from benign insulinomas. 
Another biochemical study that may be helpful in 
identifying patients with malignant insulinomas is 
human chorionic gonadotropic (hCG) hormone 
level. Increased plasma levels of the alpha and beta 
fractions of hCG have been found in patients with 
malignant islet-cell tumors. These fractions have 
not been elevated in any of the 41 benign 
insulinomas studied so far [9]. When levels of this 
hormone are elevated, the diagnosis of islet-cell 
malignancy becomes likely, but a normal level does 
not rule out malignancy. Other studies that can be 
used in the preoperative assessment of insulinoma 
patients include technetium liver scans which will 
identify cold areas consistent with liver metastases, 
pan visceral arteriography which will demonstrate 
hypervascuiar liver densities as small as 1.5 cm, and 
computed tomography (CT) scans with contrast 
enhancement. Unfortunately, many patients with 
metastatic insulinomas have very small metastases 
and these studies may all be negative. Selective 
portal venous sampling can be useful to localize a 
single source of pancreatic insulin hypersecretion 
or to demonstrate diffuse islet-cell hypersecretion. 
Portal venous samples can also help to identify liver 
metastases especially when compared to simul- 
taneously drawn hepatic venous samples [16]. The 
ratio of hepatic to portal vein insulin is affected by 
hepatic insulin extraction and must, therefore, be 
interpreted with caution. 
Diazoxide testing is done in all patients with 
proven hyperinsulinism. This study, which should 
be performed prior to any other definitive treat- 
ment, may help to determine suppression sensitiv- 
ity of tumor or hyperplastic islet tissue. Diazoxide 
should be given with a natriuretic diuretic in order 
to eliminate the salt-retaining effects of diazoxide. 
Hirsuitism is another side effect of diazoxide which 
can occur when the drug is administered long-term. 
Malignant islet-cell tumors that produce insulin 
can be treated by antihormonal therapy and/or 
antitumor therapy when surgical cure cannot be 
attained. It is clear that the development of 
diazoxide (Proglycem ~) represents a major thera- 
peutic advance [9, 15]. This drug directly inhibits 
release of insulin by the beta cells of the pancreas. 
The mechanism embodies stimulation of alpha ad- 
renergic receptors with inhibition of cyclic AMP 
phosphodyesterase. The latter effect results in high 
plasma levels of cyclic AMP which in turn enhances 
glycogenolysis. The dose varies from 150 to 450 
mg/day. Several other drugs may prove useful to 
inhibit insulin release including Inderal | chlor- 
promazine, and cortisone. 
The single most important antitumor drug avail- 
able today for treating malignant insulinomas is 
streptozotocin [6, 15, 17, 18]. This drug is a broad- 
spectrum antibiotic and a naturally occurring 
nitrosourea that causes selective destruction of the 
pancreatic beta cell. It is effective in controlling 
hypoglycemia and usually results in a measurable 
decrease in tumor size. Objective reduction in tu- 
mor mass has been noted in approximately 50% of 
patients treated with streptozotocin for functioning 
malignant insulinomas but less than 20% of patients 
have a complete remission. Moreover, despite a 
favorable biochemical response in approximately 
25% of patients, treatment has not been shown to 
prolong survival significantly. Streptozotocin toxic- 
ity can affect the kidney, liver, and bone marrow. 
Renal tubular toxicity is the most serious complica- 
tion of the drug and limits the amount that can be 
administered. This complication can be avoided by 
monitering daily urinary protein losses. A weekly 
schedule of 0.5-2 g/m = administered intravenously 
has been used most frequently. Streptozotocin can 
also be used with fluorouracil and both are given 
intravenously. This combination therapy has 
achieved an overall response rate of 63% and a 
complete response rate of 33% in patients with 
advanced islet-cell carcinoma [18]. 
Two other drugs have been used with some 
success to treat malignant insulinomas. Mithromy- 
cin causes a sharp decline in plasma insulin levels 
after small intravenous doses. In 1 reported patient, 
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four 1-mg doses were followed by euglycemia for 2 
weeks and no symptoms of hypoglycemia for an- 
other 8 weeks [19]. This particular patient later died 
of unrelated disease. Adriamycin | has also been 
used occasionally to reduce insulin levels and in 2 
patients, led to remissions of 5 and 7 months, 
respectively [9]. Cardiac toxicity and bone marrow 
suppression are the principal side effects of 
Adriamycin | therapy. 
The surgical treatment of malignant insulinomas 
is resection whenever possible [1, 4, 6, 8]. Locally 
invasive tumors in the body and tail can usually be 
excised along with peripancreatic lymph nodes. A 
Whipple resection may be indicated when a tumor 
in the head of the pancreas is locally invasive and 
the patient has no liver metastases. When there is 
evidence of surgical incurability because of distant 
metastases, every effort should be made to debulk 
as much primary and secondary tumor as possible. 
Reducing the mass of functional tissue may offer 
significant palliation and decrease the doses of 
chemotherapy necessary to control the patient's 
symptoms [8]. 
Gastrinomas 
The Zollinger-Ellison syndrome (ZES) was orig- 
inally characterized by intractable peptic ulcer dis- 
ease, multiple or jejunal ulcers, and a non-beta 
islet-cell malignant tumor (gastrinoma) with liver 
metastases [14]. Subsequent to the original report in 
1955, great interest in this fascinating syndrome 
rapidly developed. With clinical awareness and the 
availability of an assay for gastrin, diagnosis of this 
disease became more frequent and occurred at an 
earlier stage than in patients seen before 1970. After 
a decade of clinical experience with the ZES, it was 
estimated that more than 60% of gastrinomas were 
malignant with metastases to lymph nodes and/or 
the liver at the time of diagnosis [10-12, 14]. The 
standard treatment for the disease became total 
gastrectomy. Thus, surgical treatment of the ZES 
was initially directed at the target organ. No direct 
attempt was made to cure the islet-cell neoplasm. It 
was soon learned that any operation that spared 
even a small portion of stomach might lead to 
unremitting peptic ulcer disease. At first, surgeons 
made no attempt to resect the pancreatic islet-cell 
disease even when no metastases were apparent at 
operation. In a few cases, however, cures were 
reported after resection of either a duodenal or 
pancreatic gastrinoma that was apparently benign. 
It later became apparent that, although many ma- 
lignant gastrinomas are very slow growing, eventu- 
ally long-term survivors of total gastrectomy will be 
likely to die from liver metastases [10-12, 14]. In 
some cases this occurred inexorably within a few 
years, while in others the course was slowly pro- 
gressive. Surprisingly, a small group of patients 
showed regression of liver metastases after total 
gastrectomy, prompting Friesen to speculate that a 
gastric factor might be necessary in some cases to 
promote tumor growth [4, 12]. 
During the past decade, a number of events have 
occurred that led to re-evaluation of the manage- 
ment of the ZES. Perhaps most important was the 
introduction of potent H2-blocking drugs which 
effectively inhibit the effects of gastrin on the pari- 
etal cell. For the first time these drugs achieved 
some measure of control of the severe ulcer 
diathesis in most patients with the ZES. This made 
performance of elective surgical procedures in ZES 
patients possible. Furthermore, total gastrectomy 
was no longer mandatory, particularly if good drug 
control had been demonstrated preoperatively [13, 
20.22]. Because of the high incidence of malig- 
nancy, some authors advocated no other treatment 
other than H2-blockers, claiming that total 
gastrectomy was meddlesome and that attempts at 
surgical cure were futile. 
The second major advance in managing ZES was 
the development of sensitive radioimmunoassay for 
gastrin and a provocative study (secretin stimula- 
tion) to prove that elevated gastrin levels were due 
to the presence of a gastrinoma [4, 12, 22, 23]. This 
allowed for more precise diagnosis at an earlier 
stage than had ever before been achieved. As a 
result of these advances, many patients who had 
been diagnosed with rather typical peptic ulcer 
disease after short histories turned out to have early 
forms of ZES. These patients usually present with 
intermittent or persistent diarrhea. Other patients 
with ZES that are now being diagnosed before clini- 
cal symptoms become severe are those with MEN I 
syndrome. These patients all have asymptomatic 
hyperparathyroidism [5]. Regular screening has de- 
tected hypergastrinemia in this group as well as in 
MEN I patients who have been symptomatic. 
The last development to influence the surgical 
treatment of the ZES is the development of 
percutaneous transhepatic selective pancreatic ve- 
nous sampling which allows for precise localization 
of the source or sources of hypergastrinemia. When 
this procedure is combined with hepatic venous 
sampling, it is possible to predict the presence or 
absence of hepatic metastases [24]. In conjunction 
with selective arteriography and CT scanning of the 
liver, our ability to define the extent of disease has 
been vastly improved. The application of these 
advances has caused a gradual evolution in the 
philosophy of the treatment of the ZE syndrome. 
The goal of management today is to identify those 
ZES patients who have localized tumors of the 
pancreas or the duodenum that have not metasta- 
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Fig. 1. Computed tomographic (CT) scan of liver demon- 
strating multiple metastases from islet-cell carcinoma of 
the pancreas in 54-year-old man. 
sized. Surgical therapy is directed at the primary 
disease whenever  possible. It has become increas- 
ingly clear that some patients, particularly those 
with sporadic gastrinomas, are curable. Total 
gastrectomy or any other ulcer procedure can be 
avoided in this group, it is estimated that at least 
20% of ZES patients are candidates for a curative 
procedure.  This may, howver,  require a partial 
pancreatic resection. In some cases, enucleation of 
the tumor may suffice. We have recently identified 3 
patients who were candidates for local tumor re- 
section; the pancreas and stomach were left intact 
[24]. These patients are free of symptoms and have 
normal basal and secretin-stimulated gastrin levels. 
Selective pancreatic and hepatic venous hormone 
sampling was used successfully to identify these 
ZES patients prior to operation. 
Once the diagnosis of hypergastrinemia due to a 
sporadic gastrinoma has been firmly established, 
selective visceral arteriography is used for possible 
identification of the primary tumor and/or liver 
metastases. Many gastrinomas and small hepatic 
metastases will not be demonstrated by this tech- 
nique and other localization studies are indicated. 
CT scanning will show most primary tumors larger 
than 2 cm as well as hepatic metastases larger than 
1.5 cm (Fig. 1). If  there is no evidence of metastatic 
gastrinoma with these techniques, selective pancre- 
atic and hepatic venous gastrin sampling is per- 
formed. If  this study shows gastrin secretion from a 
localized pancreatic or duodenal source, it may be 
possible to cure the patient. Nevertheless,  at ex- 
ploratory celiotomy, the liver and peripancreatic 
lymph nodes should be carefully evaluated. When 
the preoperat ive evaluation has demonstrated meta- 
static disease or metastases are found at operation, 
the surgical treatment of malignant ZES is individu- 
alized. In most younger and good-risk older pa- 
tients, total gastrectomy may still be the procedure 
of choice. In addition, an attempt to resect the 
gastrinoma and its metastases should be considered 
in selected cases. As an example, in the recent case 
of a 17-year-old male, we performed a left lateral 
hepatic segmentectomy for a large single metastasis 
in addition to a total gastrectomy and distal pancre- 
atectomy. Surprisingly, his serum gastrin levels 
have remained normal for a 1-year period. Until 
recently,  we usually performed a total gastrectomy 
even when only a single lymph node was found to 
be involved with metastases and the liver was 
normal to palpation. However ,  we now have ac- 
cumulated a group of 7 ZES patients whose only 
evidence of disease was a single lymph node. They 
have shown no recurrence over  an extended period 
of time and continue to have normal basal serum 
gastrin levels which do not respond to secretin 
administration. Four  of these patients had concomi- 
tant total gastrectomies which may not have been 
necessary. The majority of patients with metastatic 
peripancreatic lymph nodes have palpable pancre- 
atic tumors. Our current policy is to resect the 
tumor and involved lymph nodes. We now wait for 
the results of follow-up gastrin testing before mak- 
ing a decision for or against total gastrectomy. 
Patients with extensive hepatic metastases are 
candidates for chemotherapy.  Some patients have 
shown a good response to streptozotocin and/or 
5-fluorouracil (5-FU). When systemic chemother- 
apy is effective and well-tolerated, it may be used 
intermittently on a long-term basis. In the patients 
failing to respond or to tolerate systemic chemo- 
therapy, we are currently using an implantable 
pump for hepatic artery chemotherapy infusion. 
The early results with this technique have been 
encouraging. 
Patients with ZES as a component  of the MEN I 
syndrome comprise more than a third of the total 
population of ZES patients. The ZES patients can 
be identified by their family history or the presence 
of concomitant hyperparathyroidism. Their distinc- 
tive pancreatic disease merits special emphasis. 
Using histological and immunohistochemical 
techniques, we have recently examined the tumors 
and nontumorous pancreata from 14 patients with 
the MEN I syndrome [5]. We found diffuse disease 
of the islet cells characterized by nesidioblastosis, 
hyperplasia, and microadenomatosis  in all and mul- 
tiple tumors in most. This evidence of diffuse islet- 
cell disease suggests that pancreatic operations less 
than total pancreatectomy are unlikely to cure 
hypergastrinemia in most MEN I patients. 
During the past 5 years, all MEN I patients with 
ZES had pancreatic venous hormone sampling [24]. 
Most of these patients have had multiple or diffuse 
sources of gastrin secretion from the pancreas or 
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duodenum. However ,  in 4 palients, localized gas- 
trin secretion was found and, at operation, pancre- 
atic tumors were enucleated and distal pancre- 
atectomies were performed. These patients are not 
cured but each has been asymptomatic without the 
need for gastrectomy or cimetidine during a follow- 
up period ranging from 1 to 4 years. All 4 have 
elevated serum gastrin levels when stimulated with 
secretin and basal levels at the upper limits of 
normal. We anticipate that these patients may even- 
tually require further medical or surgical therapy. 
A total pancreatectomy is the only procedure that 
may be curative in the MEN 1 patient with no 
evidence of metastatic gastrinoma. Nevertheless,  
this operation is not recommended in the treatment 
of ZES. The benefits of this operation are out- 
weighed by the operative mortality rate and long- 
term morbidity of insulin-dependent diabetes. Fur- 
thermore,  after either total pancreatectomy or a 
Whipple resection for ZES, previously occult liver 
metastases may appear. A total gastrectomy in 
addition to a total pancreatectomy is contraindicat- 
ed because the combined procedures are poorly 
tolerated. 
The malignant potential of small islet-cell tumors 
in the MEN I patients should not be ignored, 
however.  Their  early detection and excision may 
prevent  tumor-related deaths. We recommend 
distal pancreatectomy with enucleation of other 
functional and "s i len t"  tumors found in the pancre- 
atic head in potentially curable patients. Our long- 
term follow-up of all MEN I patients includes 
periodic CT examination of the remaining pancre- 
atic head and reassessment of gastrointestinal-pan- 
creatic hormone levels at 1-year intervals. 
G l u c a g o n o m a s  
The first well-documented patient with a glucagon- 
secreting tumor was described by McGavran and 
associates in 1966 [2]. However ,  the syndrome was 
not widely recognized until Mallison et al. reported 
9 patients with common findings in 1974 [25]. These 
authors described the clinical features of the syn- 
drome, including: (a) a characteristic dermatitis 
(necrolytic migratory erythema); (b) diabetes mel- 
litus; (c) a normochromic,  normocytic anemia; (d) 
weight loss; (e) glossitis; (f) hypoaminoacidemia; (g) 
elevated blood glucagon levels; and (h) alpha-cell 
tumor of the pancreas. Most patients are 
malnourished at the time of diagnosis. Significant 
weight loss has occurred because of the catabolic 
effects of glucagon. Despite normal coagulation 
studies, these patients also have a high incidence of 
venous thrombosis.  Pulmonary emboli are common 
and have been reported even in patients on 
anticoagulation therapy. 
In most cases, the glucagonoma syndrome occurs 
as a late manifestation of the disease. The majority 
of patients already have metastatic disease and are 
unlikely to be cured by surgical resection, in a 
collective review of the 45 patients reported 
through 1978, Higgins found that two-thirds of the 
patients were incurable at the time of their initial 
exploration [26]. 
Localized tumors are treated by pancreatic re- 
section. A Whipple resection is indicated for large 
tumors in the head of the pancreas.  This may be 
justified even when metastases are present in order 
to alleviate the debilitating effects of excess 
glucagon. An alternative operation in some patients 
is a subtotal (95%) pancreatectomy.  An aggressive 
surgical approach is indicated because the catabolic 
effects of glucagon may be palliated by debulking 
the tumor followed by chemotherapy.  One of our 
patients with a 10-cm tumor in the head of the 
pancreas was treated by 95% pancreatec tomy even 
though 2 small hepatic metastases were present. 
The effects of hormone excess may be more life- 
threatening to patients with functional endocrine 
tumors such as glucagonomas, insulinomas, and 
vasoactive intestinal polypeptideomas (VIPomas) 
than the islet-cell malignancy itself. To remove 
locally invasive tumors,  it may be necessary to 
resect a portion of the superior mesenteric vein. A 
technique we have used to reconstruct  the superior 
mesenteric vein is depicted in Fig. 2A-C. Anas- 
tomosis of the splenic vein stump to the caudal end 
of the superior mesenteric vein restores mesenteric 
venous inflow to the liver. Even in patients with 
liver metastases, resection of the tumor can result 
in rapid resolution of the dermatitis within 48 hours. 
Similar results have been reported by others after 
palliative procedures for glucagonomas [4, 23, 25, 26]. 
Because of the long-standing, debilitating 
cachexia, patients with glucagonomas should be 
prepared preoperatively with hyperalimentation. 
Antibiotic therapy is indicated in patients with 
severe skin infections. Steroid therapy may be used 
preoperatively,  on a short-term basis, if the skin 
rash is severe. Low doses of  insulin may be re- 
quired to control the diabetes caused by the 
hyperglucagonemia. The high risk of venous 
thrombosis must be considered [25]. These patients 
should be well-hydrated, and treated with low doses 
of heparin before and after operation and provided 
with elastic support stockings. 
The majority of patients with sporadic glucagon- 
omas are candidates for chemotherapy after debulk- 
ing operations because of unresectable metastases 
[4, 26]. While liver metastases should be treated 
generally by wedge resection, several other tech- 
niques may be considered. Selective hepatic arterial 
ligation has been used by some with limited suc- 
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Fig. 2A. Artist's drawing of 10-cm malignant glucagonoma arising in the pancreatic head and extending into the neck and 
uncinate process. The tumor encased and locally invaded the superior mesenteric vein. The patient, a 56-year-old man, had 
2 small hepatic metastases and a debilitating glucagonoma syndrome. B. Artist's drawing. After a 95% pancreatectomy, 
sparing the common bile duct and a duodenal rim of pancreas, the superior mesenteric vein, involved by tumor and 
bleeding from multiple minute sites, was clamped and resected. The splenic vein was clamped and saved for vein 
replacement. C. Artist's drawing. The junction of the superior mesenteric and portal vein was oversewn and the distal 
splenic vein rotated caudally and anastomosed to the proximal stump of the superior mesenteric vein. This functioned 
very well. The patient had a dramatic relief of his severe skin rash within 48 hours of operation. 
cess. Selective embolization may, in certain cases, 
prove superior to ligation. Implantable pumps for 
hepatic artery infusion chemotherapy are the most 
recently developed tools that we employ in treating 
functioning liver metastases. Streptozotocin com- 
bined with fluorouracil has reduced both hormone 
levels and tumor size. In addition to Streptozotocin 
and fluorouracil, dimethyltrizenoimidazole carbox- 
amide (DTIC) has been used to treat malignant 
glucagonomas. Prinz and associates [23] recently 
reported 2 patients with the glucagonoma syndrome 
both of whom were treated by distal pancre- 
a tectomy with good results for more than a year. 
Both patients were treated for symptomatic recur- 
rences with DTIC and had complete alleviation of 
their rashes along with a marked fall in glucagon 
levels. At least 4 other patients have been treated 
with DTIC with good responses and no major 
toxicity. The only side effect reported has been mild 
nausea. These authors consider DTIC the initial 
chemotherapeut ic  agent of choice in treating meta- 
static glucagonomas. 
The Verner-Morrison Syndrome 
Nearly all patients with the Verner-Morrison syn- 
drome present  with watery diarrhea which may be 
mild and intermittent or severe and persistent. At 
times the diarrhea can be life-threatening. Verner 
and Morrison first noted the association of severe 
diarrhea and islet-cell adenomas of the pancreas in 
1958 [3]. Their  patients also had achlorhydria and 
hypokalemia. In retrospect,  only 50% of these pa- 
tients are achlorhydric,  the remainder are 
hypochlorhydric [1, 27]. Additional finding in some 
patients include episodes of flushing and hypoten- 
sion. Most patients have a diabetic glucose toler- 
ance test. Approximately one-half of patients are 
hypercalcemic,  although they do not have primary 
hyperparathyroidism. 
Not all patients with the watery diarrhea syn- 
drome have islet-cell tumors.  Approximately 20% 
of reported patients have islet-cell hyperplasia, and 
at least 10% have nonpancreatic tumors most com- 
monly occurring in the adrenal gland, retroperito- 
neum, mediastinum, or neck [1, 3, 4]. In children, 
the most common cause of the syndrome is a 
ganglioneuroma. The majority of well-documented 
patients have elevated serum levels of vasoactive 
intestinal polypeptide (VIP). However ,  in some 
patients, only prostaglandin E2 (PGE2) or pancre- 
atic polypeptide levels have been found to be el- 
evated. 
Preoperative localization in patients with 
VIPomas can be achieved in most cases by compu- 
terized axial tomography because nearly all symp- 
tomatic tumors are larger than 3 cm in diameter ]1, 
4]. 
The definitive treatment of the Verner-Morrison 
syndrome is surgical excision of the tumor or sub- 
total pancreatectomy (80%) when hyperplasia or 
nesidioblastosis of the islet cells is the cause. Of the 
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reported cases of VIPomas, 50% have been malig- 
nant [27]. Eighty percent of these islet-cell tumors 
occurred in the body or tail of the pancreas. Incur- 
able tumors should be treated by palliative re- 
section of as much primary and secondary tumor as 
is feasible. Resection of benign VIPomas results in 
alleviation of all preoperative symptoms and meta- 
bolic abnormalities. 
Preoperatively, patients with VIPomas should be 
carefully rehydrated and electrolyte losses, particu- 
larly potassium and magnesium, replaced. At least 7 
deaths have been reported because of fluid and 
electrolyte abnormalities [1]. If metastatic disease 
precludes cure, adrenal cortical steroids should be 
considered. In some cases, steroids have effectively 
relieved the diarrhea. In patients with elevated 
PGE2 levels, prostaglandin inhibitors should be 
administered. Liver metastases that cannot be read- 
ily resected can be treated by the same techniques 
utilized for other functional islet-cell tumors. 
"Silent" and Nonfunetioning Islet-Cell Tumors 
Approximately 15% of islet-cell neoplasms produce 
hormones that have no apparent clinical manifesta- 
tions or are not detectable by current immunoas- 
says [1, 4]. These tumors often may be difficult to 
diagnosis until metastases develop or the primary 
tumor becomes so large that a mass effect produces 
symptoms. The most frequent nonfunctioning islet- 
cell tumor is the pancreatic polypeptideoma 
(PPoma). To be able to detect a tumor by its 
secretion(s) implies that the tumor is no longer 
biochemically "silent";  nonetheless, there are no 
distinct clinical symptoms associated with these 
neoplasms. Somatostatinomas have also been re- 
cently recognized by their hormonal products and 
by immunohistochemical stains of tumor tissue. 
Although a somatostatinoma syndrome has been 
described, many patients have had no symptoms or 
findings suggestive of this tumor. Both PPomas and 
somatostatinomas may arise in patients with the 
MEN I syndrome. 
The general principles of managing islet-cell tu- 
mors are similar. All should be considered malig- 
nant until proven otherwise. Many will not be 
detected until hepatic metastases are present. Un- 
fortunately, surgical treatment must be considered 
palliative, at best, in many of these patients because 
of the advanced stage of disease at diagnosis. In 
some patients surgical intervention will offer little 
benefit other than to establish a histologic diagnosis 
and stage the disease. In others, palliative resection 
may be of some benefit because of involvement of 
contiguous structures. Most patients with obvious 
metastases, however, will be candidates for chemo- 
therapy with streptozotocin, 5-FU, or DTIC. Re- 
cently, an implantable drug delivery system for 
hepatic arterial infusion chemotherapy has been 
used to treat patients with extensive liver metas- 
tases with some success. 
Pancreatic Polypeptide-Producing Tumors 
(PPomas) 
Tumors that secrete pancreatic polypeptide cause 
no distinguishing clinical symptoms that can be 
attributed to hormone excess [28]. With the devel- 
opment of a suitable immunoassay capable of de- 
tecting this hormone in blood, interest in pancreatic 
polypeptide-secreting tumors has increased mark- 
edly [29]. Elevated levels of PP have been found in 
patients with the MEN I syndrome even when a 
discrete tumor is not present [4, 28, 30]. The appar- 
ent source appears to be dysplastic islet cells which 
are universally present in MEN I patients. 
Until recently there has been a paucity of reports 
of PPomas in the literature. However, such reports 
are increasing in frequency since the greater avail- 
ability of the immunoassay and the more frequent 
use of the immunohistochemistry to identify islet- 
cell tumors excised at operation when no clinical 
syndrome had been identified preoperatively. 
During the past 5 years (1978-1983), 8 patients 
with PP-producing islet-cell tumors were treated at 
the University of Michigan [28]. No definite endo- 
crine syndrome could be recognized in this group of 
patients. Four patients presented with abdominal 
pain and weight loss. The principal complaint in 2 
patients was diarrhea and in 2 other patients was 
gastrointestinal bleeding. One of the 8 patients 
presented with jaundice and was thought to have 
adenocarcinoma of the exocrine pancreas. PPomas 
in 2 patients were associated with the MEN I 
syndrome and both cases were found to be benign 
at operation. Of the 6 patients with sporadic 
PPomas, 2 were malignant as determined by diffuse 
hepatic metastases found at the time of operation. 
Both of these patients had large pancreatic islet-cell 
tumors. Curative resections were attempted in 6 
patients. Four required pancreaticoduodenectomy 
and 2 underwent 80% pancreatectomy. All of the 
patients who underwent potentially curative re- 
sections have remained asymptomatic with blood 
PP levels that have returned to normal. Two pa- 
tients with hepatic metastases survived for 2 and 3 
years, respectively, during which time they were 
treated with streptozotocin. 
One of the patients with a solitary, sporadic 
PPoma presented with abdominal pain and intermit- 
tent diarrhea. This 74-year-old woman was found to 
have a 9-cm tumor in the mid-portion of the body of 
the pancreas and an 80% pancreatectomy was per- 
formed. The peripancreatic lymph nodes were 
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found to be free of metastatic disease and there was 
no local invasion of the pancreas. Her  diarrhea 
completely resolved and her blood PP levels have 
returned to normal and remained so during the past 
2 years. 
Another  patient, a 20-year-old woman, became 
jaundiced after symptoms of right upper quadrant 
pain and weight loss developed. By the time she 
was studied, she had developed a palpable right 
upper quadrant mass. Selective celiac angiography 
demonstrated a 15-cm tumor mass that partially 
occluded the superior mesenteric vein. At opera- 
tion, a large mass was excised by pancre- 
a t icoduodenectomy.  Although the superior mes- 
enteric vein was compressed,  it was not invaded. 
During a 3-year follow-up period, she has shown no 
evidence of metastatic disease and her PP levels 
have remained normal. 
One of the 2 patients with metastatic disease was 
a 48-year-old man whose chief complaint was ab- 
dominal pain. In his case, arteriography demon- 
strated a vascular mass in the head of the pancreas 
with multiple vascular metastases in the liver, char- 
acteristic of islet-cell tumor. This patient also had 
portal hypertension with esophageal varices. After 
a histological diagnosis was established, he was 
treated for 2 years with a combination of 5-FU, 
streptozotocin,  and Adriamycin ~. During this time, 
he experienced intermittent anorexia, diarrhea, and 
abdominal pain, became progressively cachetic, 
and died. At autopsy, the primary PPoma measured 
3 • 4 cm and was located in the distal third of his 
pancreas. The tumor locally invaded the splenic 
vein and the pancreatic duct. Metastases, ranging in 
size from 0.5 to 6 cm, were present throughout the 
liver. Additional positive lymph nodes were found 
in the periportal area. 
Discrete PP-producing tumors of the pancreas 
should be treated by enucleation or curative re- 
section whenever  possible. Whenever  a 
nonfunctional pancreatic tumor is found associated 
with liver metastases,  it must be established 
whether  or not it is of islet-cell origin. Malignant 
PPomas can be treated with streptozotocin and 
objective responses can be anticipated in about 
one-half of patients treated with this therapy [31]. 
Since an immunoassay for PP has become avail- 
able, it is evident that many islet-cell tumors, previ- 
ously considered nonfunctional,  are PPomas. In our 
experience,  more than half of the patients with 
these tumors have elevated basal PP levels [28]. 
Secretin stimulation increases PP levels in 70% of 
patients. In some cases, small PPomas may not be 
detected by a single determination of basal or 
secretin-stimulated PP. However ,  the presence of 
these tumors may be suspected by observing in- 
creasing serum PP levels over  several months. 
After resection of a tumor,  elevated serum PP levels 
should rapidly fall to normal, provided that no 
occult metastases are present.  
Friesen has reported that elevated PP levels in 
patients with the MEN I syndrome indicate multiple 
tumors of the pancreas. Because of the malignant 
potential of these islet-cell tumors,  Friesen recom- 
mends exploration and possible pancreatectomy 
resection for MEN I patients with persistently el- 
evated PP levels [4, 29]. We have observed in- 
creased PP levels in 50% of our patients with 
carcinoid syndrome, 75% of patients with 
VIPomas, and 25% of patients with gastrinomas or 
insulinomas. Thus, before recommending blind ex- 
ploration, we prefer to first localize the source of PP 
hypersecret ion by selective portal venous sampling. 
An exploratory operation can then be done if a 
pancreatic tumor has been demonstrated by venous 
sampling, CT, or angiography and no metastases 
are seen in the liver. 
Two of our patients with relatively asymptomatic 
PPomas were found to have angiographic evidence 
of liver metastases. Needle biopsy of  liver con- 
firmed the diagnosis in each case and they were 
treated with streptozotocin.  Localization studies 
have helped us to determine resectability in patients 
with PPomas. Elevated serum PP levels occurring 
in patients with MEN i syndrome may reflect 
diffuse islet-cell dysplasia resulting in nesidioblas- 
tosis or multiple adenomatosis.  Any resection short 
of total pancreatectomy will, therefore,  not lower 
the PP levels in these patients. The frequency with 
which microscopic islet-cell tumors undergo malig- 
nant changes in MEN I patients has not been 
established. At present,  we believe that pancreatic 
resections should be reserved for patients with 
clearly identified lesions. 
PPomas may be very slow growing even when 
malignant. Whether  surgical debulking of nonfunc- 
tioning islet-cell tumors facilitates cytotoxic chemo- 
therapy is not known. Even when extensive metas- 
tases are present, excellent palliation can be 
achieved in some cases with chemotherapy.  If there 
is no response to streptozotocin or fluorouracil, 
DTIC should be considered. It has been used with 
success in some patients with islet-cell malignancy 
[23]. 
Molecular heterogeneity is a feature of all mam- 
malian polypeptides studied to date. The degree of 
heterogeneity reported for these peptides has varied 
but, if demonstrated,  may be beneficial in establish- 
ing the diagnosis of malignancy. 
Plasma from 4 patients with apparently benign PP 
tumors and from 2 patients with malignant PP 
tumors was chromatographed on a Sefadex G-100 
(0.1 M formic acid) molecular sieving column [28]. 
Only 1 PP peak was observed in the group with 
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benign tumors, but one of the patients with a 
malignant tumor had 2 activity peaks. Although 
molecular sieving chromatography may prove use- 
ful in differentiating benign from malignant PPomas, 
additional studies will be necessary to establish the 
validity of this observation. 
Somatostatinomas 
Somatostatinomas are rare islet-cell tumors but 
may be more frequent than reports would indicate 
[32]. Some authors have concluded that 
somatostatin-secreting tumors may not be "silent" 
but cause a syndrome consisting of adult-onset 
diabetes, anorexia, weight loss, distention of the 
gallbladder with or without cholelithiasis, and 
achlorhydria [33]. However, these symptoms and 
findings are nonspecific and relatively common in 
elderly patients with neoplasms of the pancreas. 
Furthermore, about one-third of the reported pa- 
tients have not had all of the components of this 
"syndrome" [1, 4, 30]. It is unlikely that many new 
cases of somatostatinomas will be suspected and 
diagnosed on the basis of clinical findings alone. 
Of the 11 well-documented cases, 6 patients had 
liver metastases at the time of diagnosis. Half of the 
tumors arose in the head of the pancreas. Whipple 
resections were done in 4 but 2 died in the early 
postoperative period. The primary tumors were 
large, ranging in size from 5 to 10 cm. Five of these 
somatostatin-secreting tumors also secreted other 
hormones including calcitonin, ACTH, insulin, and 
gastrin. Streptozotocin and 5-FU were used suc- 
cessfully in several patients with unresectable le- 
sions. 
Our experience with somatostatinomas has been 
limited. In 1 patient, a 21-year-old woman with a 
large (7 cm) "insulinoma" of the pancreatic head, 
elevated somatostatin and insulin levels were deter- 
mined by selective pancreatic venous sampling [16]. 
After enucleation of the tumor, plasma levels of 
both hormones returned to normal. We have identi- 
fied somatostatin immunohistochemically with 
immunoperoxidase staining in 6 of 14 islet-cell tu- 
mors excised from patients with MEN 1 syndrome 
[5]. Clinically, each of these patients presented with 
either a Zollinger-Ellison or hypoglycemic syn- 
drome. One patient with ZE syndrome was treated 
by total gastrectomy after multiple pancreatic islet- 
cell tumors were resected. Surprisingly, staining of 
metastases in a lymph node, contiguous to the 
primary tumor, demonstrated somatostatin but not 
gastrin. 
The present evidence suggests that most patients 
with somatostatinomas will remain asymptomatic 
until the tumor is quite large. These tumors, even 
when small, should be considered malignant and 
excised. Large or locally invasive tumors may re- 
quire extensive pancreatic resection if potentially 
curable. The treatment of liver metastases is similar 
to that described for other islet-cell carcinomas. 
R~sum~ 
Les tumeurs insulaires malignes sont rares mais 
elles presentent un grand interet car si le traitement 
entra~ne exceptionnellement leur guerison il assure 
une survie des malades qui en sont porteurs. Ce 
sont en effet des tumeurs malignes ~ developpement 
lent, sensibles ~t Faction de l'association de la 
chimiotherapie et de la chirurgie. Chez certains 
sujets les tumeurs secretant de l'insuline, de la 
gastrine, du glucagon, du V.I.P. peuvent mettre en 
jeu la vie du malade sous l'effet de l 'hypersecretion 
hormonale. Le traitement chirurgical depend de ce 
fait, des caracteres fonctionnels et du degrd de 
malignite de chaque type de tumeur. En presence 
de lesions hypersecretantes l 'exerese de la tumeur 
primitive doit etre envisagee alors meme que la 
possibilite d'obtenir une guerison definitive ne peut 
6tre escomptee. I1 est aussi ~ noter que certaines 
lesions malignes ont ete traitees avec succes alors 
que les ganglions lymphatiques correspondants 
etaient dej~ envahis. Si l 'operation est contre-indi- 
quee en presence de metastases hepatiques la 
duodenopancreatectomie cdphalique s'applique aux 
tumeurs insulaires cdphaliques qu'elles s'accompa- 
gnent ou non d'un envahissement des ganglions 
juxta-pancreatiques. Du fair que les metastases 
hepatiques sont souvent multiples et qu'elles 
interessent les deux lobes Faction sur le foie se 
limite ~t l'dxdrese des metastases accessibles ~ la 
resection hepatique segmentaire. Les tumeurs 
insulaires malignes qui ne sont pas hypersecrd- 
tantes reldvent de la chimiothdrapie par voie 
gendrale ou de la chimiotherapie regionale des lors 
qu'elles s'accompagnent de metastases. C'est 
seulement lorsque ces lesions entrainent une 
obstruction de la voie biliaire principale ou du 
duodenum que la resection ou les anastomoses de 
derivation sont indiquees. La chimiothdrapie par 
voie gendrale ou par la voie de l'artere hdpatique ou 
encore l'embolisation de cette derniere 
representent les meilleures methodes de traitement 
des metastases hdpatiques. L'emploi recent de 
pompes ~t infusion de l'artere hdpatique a donne des 
rdsultats interessants chez ces malades. Les agents 
chimiques les plus efficaces sont la streptozotocine, 
le DTIC et le Fluorouracil. 
Resumen 
Aunque los tumores malignos de celulas insulares 
del p~increas son raros, estos constituyen un grupo 
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importante  entre las neoplasias pancrefiticas por 
cuanto el t ra tamiento apropiado con frecuencia 
resulta en una paliacidn efectiva a pesar  de que la 
curacidn sea poco frecuente.  En general estos 
tumores  son de crecimiento lento y la combinacidn 
de la cirugfa con quimioterapia puede llegar a ser 
beneficiosa. En algunos pacientes con tumores  que 
hipersecretan insulina, gastrina, glucagdn o VIP 
(polip6ptido vasoact ivo intestinal), los efectos 
hormonales  del neoplasma pueden poner  en peligro 
la vida. Por ello el t ra tamiento quirtirgico debe 
considerar  tanto las caracterist icas funcionales 
como las de malignidad de cada tumor en particular. 
En muchos  pacientes con neoplasmas funcionantes,  
el debul tamiento quirtirgico del tumor primario 
puede estar  indicado cuando la reseccidn curat iva 
no es realizable. Algunas neoplasias malignas 
pueden ser curadas mediante una reseccion 
pancre~itica adecuada a pesar  de que los ganglios 
linfS.ticos peripancrefiticos ya  se hallen afectados.  
Afin cuando el procedimiento de Whipple no estfi 
indicado en presencia  de metfistasis hepfiticas, esta 
operacidn puede curar  tumores  localizados en la 
cabeza  del p~increas y/o en los ganglios linf~iticos 
peripancre~iticos. Debido a que las met~istasis 
hep~iticas generalmente  son mtilitples y afectan a 
ambos  ldbulos, las resecciones hep~iticas, 
diferentes de las resecciones en curia para lesiones 
funcionantes localizadas en la periferie del higado 
no est~in indicadas. Los  tumores  malignos no 
funcionantes de c61ulas insulates probablemente  
deben set  t ratadas con quimioterapia sist6mica o 
regional cuando se encuentren en fase metastfisica. 
Las  resecciones quirtirgicas o los procedimientos 
derivat ivos infrecuentemente  son de utilidad en 
aquellos casos en los cuales el tumor  primario causa 
obstruccidn duodenal o del conducto biliar. Los  
m6todos de mayor  efectividad en el control de las 
metdstasis  hepfiticas son los de quimioterapia 
sistdmica y arterial hepfitica. Una alternativa es la 
embolizacidn selectiva de la arteria hep~itica. 
Recientemente  ha venido a set  utilizada una bomba  
implantable de infusidn arterial hepfica con 
resultados halagadores en este grupo de pacientes.  
Los  agentes quimioterapduticos que han probado 
ser de mayor  efectividad en el t ratamiento de las 
metfistasis hep~iticas inctuyen la estreptozotocina,  
la dimeti l tr izenoimidazol carboxamida  (DTIC) y el 
Fluorouracilo.  
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